Welcome to ebovac2

The EBOVAC2 project is one of 8 projects funded under IMI Ebola+ programme that was launched in response to the Ebola virus disease outbreak. The project aims to assess the safety and efficacy of a novel prime boost preventive vaccine regimen against Ebola Virus Disease (EVD).

To expedite the development of the vaccine regimen, Phase 2 and Phase 3 trials will be carried out in parallel and therefore coordinated by two separate teams within EBOVAC1 (Phase 1 trials and Phase 2B large scale safety and immunogenicity study) and EBOVAC2 (Phase 2 trial) projects. Find out more about Phase 2.

© Janssen

Between them, the EBOVAC projects will assess, through phase 1, 2 trials and Phase 2B study in Europe and Africa, the safety and tolerability of the vaccine regimen in response to the urgent public health need raised by the Ebola epidemic.

Currently, there are no proven therapies to treat Ebola or vaccines to prevent infection/disease. Thus, in view of the current Ebola epidemic, on September 5th 2014, the World Health Organisation identified the progression of Ebola vaccine candidates currently in development as an urgent public health need. Several candidate vaccines are available. No vaccines have been approved for human use to prevent or treat Ebola, although several are promising in animal models (such as the vaccine regimen being proposed in the EBOVAC programme). In view of the urgency of these outbreaks, the international community is seeking to find ways to accelerate the evaluation and use of these products.

Based on the WHO recommendations, EBOVAC2 will provide data to assess the safety, immunogenicity and efficacy of a novel candidate vaccine regimen to prevent Ebola virus disease (EVD).

Find out more about the EBOVAC1 trials:
Phase 1:
Trial countries: UK and selected African countries currently unaffected by Ebola

Phase 2B large scale safety and immunogenicity study

More information coming soon...